On August 28, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s Mounjaro to lower the risk of cardiovascular events, including heart attacks, in patients with Type 2 diabetes. The milestone expands the therapeutic footprint of the dual GLP-1 and GIP receptor agonist beyond blood sugar management and weight control.
The Bottom Line
- The New Indication: Mounjaro is officially cleared by the FDA to reduce heart attack and stroke risks for individuals managing Type 2 diabetes.
- The Clinical Benchmark: In clinical data submitted to regulators, patients taking Mounjaro demonstrated an 8% lower rate of major adverse cardiovascular events compared to those taking Eli Lilly’s GLP-1-only drug, Trulicity.
- Future Horizons: Ongoing trials are currently investigating whether related compounds like Zepbound can prevent primary and secondary cardiac events in populations without diabetes.
Expanding Beyond Blood Sugar: The Cardiovascular Shift
The intersection of metabolic health and cardiology has officially reached a new inflection point. For years, the conversation surrounding incretin-based therapies focused heavily on glycemic control and scale-tipping weight loss. Here is the kicker, though: for patients living with Type 2 diabetes, cardiovascular disease remains the primary driver of mortality. By securing this new FDA indication, Mounjaro transitions from a specialized diabetes management tool into a broader metabolic health intervention.
According to Dr. Rachel Batterham, senior vice president of medical innovation and external engagement for cardiometabolic health at Eli Lilly, targeting this demographic was a necessary clinical priority. “This study was in patients with Type 2 diabetes, in whom the No. 1 cause of death is cardiovascular disease,” Batterham notes, emphasizing why mitigating cardiac risk is critically important for this patient base.
Dissecting the Data: Mounjaro Versus Trulicity
The regulatory approval rests on a rigorous comparative trial design. Rather than relying solely on a standard placebo-controlled trial, Eli Lilly pitted Mounjaro directly against an established heavyweight in its own portfolio: Trulicity. While Trulicity targets solely the GLP-1 receptor and has historically demonstrated a 12% reduction in cardiovascular events compared to placebos, Mounjaro activates both GLP-1 and GIP incretin hormones.
In the head-to-head trial data presented to the FDA, patients taking Mounjaro achieved an 8% lower rate of heart attack, stroke, or cardiovascular death than those maintained on Trulicity. Batterham explains the high standards the company set for the research team: “We set ourselves a very high bar.”
| Therapy | Target Mechanism | Primary Regulatory Status | Cardiovascular Benefit Metric |
|---|---|---|---|
| Mounjaro (Eli Lilly) | GLP-1 and GIP receptor agonist | Type 2 Diabetes, Blood Sugar, Heart Event Risk Reduction | 8% lower rate of heart attack, stroke, or cardiovascular death vs. Trulicity |
| Trulicity (Eli Lilly) | GLP-1 receptor agonist | Type 2 Diabetes, Blood Sugar | 12% lower risk of heart events vs. placebo in past studies |
| Ozempic (Novo Nordisk) | GLP-1 receptor agonist | Type 2 Diabetes, Heart Disease Risk Reduction | 20% lower risk of heart disease risk |
| Wegovy (Novo Nordisk) | GLP-1 receptor agonist | Overweight and Obesity, Heart Disease Risk Reduction | 20% lower risk of heart disease risk |
Navigating the Competitive Landscape
The marketplace for incretin therapies is fiercely contested, with rival drugmaker Novo Nordisk holding established cardiac indications for both its diabetes treatment Ozempic and its weight-loss formulation Wegovy, each boasting a documented 20% reduction in heart disease risk. Because of the specific design of Lilly’s trial—which used Trulicity as the active comparator rather than a neutral placebo or a direct competitor—researchers caution that these percentage figures cannot be directly cross-compared against Novo Nordisk’s catalog.
The competitive rivalry continues to drive aggressive clinical research across the pharmaceutical sector. Eli Lilly is actively tracking patient outcomes in a separate, massive trial evaluating Zepbound—the brand name for the weight-loss iteration of the drug—in individuals without Type 2 diabetes. According to Batterham, that ongoing trial is tracking whether the treatment can successfully prevent both first-time and secondary cardiovascular events in non-diabetic cohorts.
For now, physicians treating patients with Type 2 diabetes have a clarified mandate. Clinicians can directly inform patients already taking Mounjaro that the therapy offers dual utility: keeping blood sugar in check while actively driving down the statistical threat of a cardiac event. Meanwhile, patients utilizing Zepbound solely for weight management must wait for data. As Batterham points out regarding the non-diabetic demographic, “What we could say is that we know people with Type 2 diabetes see this benefit, but as yet we don’t have the data to say that this same benefit applies in people without diabetes—but we will have those data next year.”
Related reading
